Telomir Pharmaceuticals, INC 8-K filings

Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data demonstrating Telomir-Zn's efficacy in suppressing tumor growth and metastasis in prostate and triple-negative breast cancer models.

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing Telomir-Zn restored insulin sensitivity and improved glucose homeostasis in a Type 2 diabetes zebrafish model.

Telomir Pharmaceuticals has appointed Andriy Mushak as its new fractional Chief Financial Officer, effective June 6, 2026.

Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study detailing positive results for Telomir-Zn in a Wilsons disease zebrafish model, showing improved survival and multiple endpoint benefits.

Telomir Pharmaceuticals announced FDA clearance of its Investigational New Drug application for Telomir-Zn, paving the way for a Phase 1/2 trial in triple-negative breast cancer.

Telomir Pharmaceuticals, Inc. has completed the acquisition of TELI Pharmaceuticals, Inc., consolidating global rights for its Telomir-1 (Telomir-Zn) platform.

Telomir Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders.

Telomir Pharmaceuticals announced the submission of an Investigational New Drug application to the FDA for Telomir-1 (Telomir-Zn) to treat advanced and metastatic Triple-Negative Breast Cancer.

Telomir Pharmaceuticals, Inc. shareholders approved the acquisition of Teli Pharmaceuticals, Inc., amendments to its incentive plan, and changes to its bylaws at the 2025 Annual Meeting.

Telomir Pharmaceuticals announced positive preclinical in vitro data for Telomir-Zn, demonstrating significant tumor cell mortality in human triple-negative breast cancer models.

Telomir Pharmaceuticals reports new preclinical data for Telomir-Zn, indicating an epigenetic modulation mechanism relevant to cancer and aging.

Telomir Pharmaceuticals received a Nasdaq notice for failing to hold its annual shareholder meeting within the required timeframe, but expects to regain compliance.

Telomir Pharmaceuticals announced positive preclinical results for Telomir-1 in aggressive triple-negative breast cancer animal models, showing significant tumor growth and metastasis reduction.

Telomir Pharmaceuticals' CEO Erez Aminov was awarded a $400,000 short-term incentive, a contingent $150,000 IND milestone, a 3% TELI acquisition advisory award, and a base salary increase to $500,000.

Telomir Pharmaceuticals announced favorable GLP safety results for its lead candidate, Telomir-1, clearing a critical hurdle for first-in-human clinical development.

Telomir Pharmaceuticals announced new preclinical data showing its drug candidate, Telomir-1, significantly reduces PSA levels in human prostate cancer cells and tumor volume in mouse models.

Craig Eagle has resigned from the Board of Directors of Telomir Pharmaceuticals Inc., effective November 14, 2025, with no reported disagreements.

Telomir Pharmaceuticals announced new preclinical findings showing its investigational compound, Telomir-1, effectively kills aggressive human leukemia cells in laboratory settings.

Telomir Pharmaceuticals reports new preclinical data showing its lead compound, Telomir-1, significantly reduced intracellular iron more effectively than FDA-approved Deferoxamine.

Telomir Pharmaceuticals reported new preclinical data showing its investigational compound Telomir-1 effectively resets cancer defense systems in an aggressive prostate cancer model, outperforming Rapamycin and chemotherapy.

Telomir Pharmaceuticals has entered a binding LOI to acquire TELI Pharmaceuticals, unifying worldwide intellectual property rights for its lead candidate, Telomir-1, and securing up to $5 million in shareholder contributions.

Telomir Pharmaceuticals announced new lab data showing its drug candidate, Telomir-1, effectively reduced the survival of aggressive human pancreatic cancer cells in vitro.

Telomir Pharmaceuticals announced new findings that Telomir-1 selectively kills aggressive triple-negative breast cancer cells by disrupting iron-dependent energy pathways.

Telomir Pharmaceuticals announced new preclinical findings for Telomir-1, demonstrating its ability to reset DNA methylation of key tumor suppressor genes in aggressive prostate cancer models.

Telomir Pharmaceuticals announced new in vitro data showing Telomir-1 targets additional histone demethylase families, representing a novel and broad epigenetic therapy.

Telomir Pharmaceuticals reports Telomir-1 outperformed Rapamycin and chemotherapy in preclinical prostate cancer models by reactivating a key tumor suppressor gene.

Telomir Pharmaceuticals, Inc. completed the sale of 1.55 million common shares to institutional investors, generating approximately $2.9 million in gross proceeds.

Telomir Pharmaceuticals announced new in vitro data for its lead drug candidate, Telomir-1, revealing a dual mechanism of action targeting DNA methylation and Wnt signaling in cancer and age-related diseases.

Telomir Pharmaceuticals announced new in vitro data showing its lead drug candidate, Telomir-1, inhibits key epigenetic enzymes linked to cancer, autoimmune, neurodegenerative, and metabolic diseases.

Telomir Pharmaceuticals announced new preclinical results for Telomir-1, demonstrating its ability to restore mitochondrial function and reduce oxidative stress in diseased human cells without inducing proliferation.